FIG. 1.

Distribution of variants among group M HV-1 integrase sequences. The consensus subtype B sequence is shown at the top of each 40 amino acid section. Beneath the consensus B sequence is the number of annotated sequences containing an unambiguous amino acid at the indicated position with the number of such sequence ranging from 3730 to 4435. All variants reported at a level of ≥0.5% of sequences are indicated. Gray shading surrounds the central core domain residues. Boxes indicate the signature HHCC zinc-binding motif in the N-terminal domain and the DDE active site residues in the central core domain. Positions at which primary INI-resistance mutations for raltegravir and elvitegravir have been reported are indicated by “★”. Positions at which accessory INI-resistance mutations for raltegravir and elvitegravir have been reported are indicated by “+”. Positions at which INI-resistance mutations for other inhibitors have been reported are indicated by “•”.